Study: Newer hepatitis B drug is more effective  | Health News | Advocate.com

||  Health News  ||
03/11/06-03/13/06
Study: Newer hepatitis B drug is more effective

Two studies published Thursday in The New England Journal of Medicine show that Bristol-Myers Squibb's new drug Baraclude (entecavir) is more effective against hepatitis B than GlaxoSmithKline's Epivir (lamivudine). The two drugs are among five approved for hepatitis B treatment in the United States.

In an editorial accompanying the studies, Jay Hoofnagle of the National Institute of Diabetes and Digestive and Kidney Diseases wrote, "Entecavir seems to be an outstanding agent for treating chronic hepatitis B" due to its effectiveness and the low rate at which the virus develops resistance to it.

The researchers, led by Ting-Tsung Chang of the National Cheng Kung University Medical College in Taiwan, reported that 72% of 314 patients treated with entecavir experienced improvement after 48 weeks of treatment. Only 62% of 314 lamivudine-treated patients showed improvement in the same time period. In the entecavir group, 67% of patients achieved an undetectable level of hepatitis B virus particles; 35% of the lamivudine patients achieved undetectable levels.

"Perhaps the most promising aspect of entecavir therapy has been the low rate of antiviral resistance," Hoofnagle wrote. After four years of lamivudine therapy, 70% to 80% of patients develop resistance to the drug. However, Hoofnagle warned that treatment can still be complicated because "it is still unclear who should be treated, with which agent (or combination of agents), for how long," and how best to monitor patients. In addition, he wrote, "Once treatment with oral antiviral agents has begun, it is difficult to stop" since the virus tends to rebound when therapy is halted.

Bristol-Myers Squibb, entecavir's maker, funded the study. In the United States, a month's supply of 0.5-milligram entecavir tablets costs about $650, which is four times the cost of lamivudine.

Hepatitis B is a common sexually transmitted disease among gay men. Although vaccines exist to prevent both hepatitis A and B infections, the Gay and Lesbian Medical Association says fewer than half of sexually active gay men have received the vaccines. (Reuters, with additional reporting by Advocate.com)

© 2008 Reuters. Click here for restrictions.

Reader Comments

These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.

Be the first to comment on this story.

Back to top

Submit a comment for this story:

*Type your comment here (Required, 1000 characters max.):

*Name (Required): 

*Hometown (Required): 

*E-mail address: (Required, but will not be displayed)

Is this comment for publication? 
Yes   No

Daytime phone number: (Required for print publication only and will not be displayed)

If you would like to submit a comment for posting, please fill out the form above. 

All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.

Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.

Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.